PHATHOM PHARMACEUTICALS, INC. Payments of Stock Issuance Costs
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Payments of Stock Issuance Costs of $1.30 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2019-11-25
- 2019-09-30: Payments of Stock Issuance Costs 9 month $1.30M.
| Period end | Payments of Stock Issuance Costs 9 month |
|---|---|
| 2019-09-30 | $1.30M 10-Q · filed 2019-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |